HC Wainwright reiterated their buy rating on shares of Nuvation Bio (NYSE:NUVB – Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $8.00 price objective on the stock. HC Wainwright also issued estimates for Nuvation Bio’s Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.08) EPS, Q4 […]